Article Text

Download PDFPDF
Randomised controlled trial
While hormone therapy unlikely harmful in younger postmenopausal women at low CV risk, protective effects cannot be claimed
  1. Beth L Abramson
  1. Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Canada
  1. Correspondence to: Beth L Abramson
    Division of Cardiology, St. Michael's Hospital, University of Toronto, 30 Bond Street Toronto, Ontario, Canada M5W 1B8; abramsonb{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


The last 10 years have clarified the issues regarding postmenopausal hormone therapy (HT) and cardiovascular disease (CVD). Prior to the large, randomised women's health initiative (WHI),1 observational studies had suggested a protective cardiovascular (CV) effect. The WHI showed no benefit, and increased thromboembolic and CV events in women taking HT. The WHI findings have been challenged because of the older age of the participants.2 A ‘critical timing’ hypothesis has been suggested to try to explain how the use of HT at the onset of menopause could be cardioprotective, whereas later initiation could cause adverse events.3– ,6 …

View Full Text


  • Competing interests None.